Specialised Therapeutics Australia   Report issue

For profit Phase 2
Founded: Kew Australia (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2015
NCT02215447
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

carboplatin (paraplatin) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2